Arkolith/Insider Trading/LXEO/Form 4

Tamayo Louis Edward

Chief Financial OfficerLexeo Therapeutics, Inc. (LXEO) · full profile →Form 4 · filed Jul 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$21K
Net Open-Market Flow
-$21K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 1, 2026Sell(S)5K$4.49$21K97K
Jun 29, 2026Grant(A)12K—$0102K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0002083206-26-000005) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML